Inovio Pharmaceuticals(US:INO) Globenewswire·2026-03-21 17:25Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [2] - The lead plaintiff acts on behalf of other class members in directing the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3] Group 3: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [4] - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [4] - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements [4]